---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021564"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:38:10.897494+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH

## Summary
- Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.
- Cash, equivalents & short-term investments $427.8M pro forma $462.8M after $25M BMS equity and $10M Hercules draw.
- $125M Hercules term loan: $10M drawn immediately, up to $115M additional upon milestones; runway into 2026.
- Updated ziftomenib Phase 1 data from KOMET-001 accepted for oral presentation at ASH Dec 10, 2022.
- AIM-HN registration trial of tipifarnib in HRAS mutant HNSCC closed to enrollment; KURRENT-LUNG trial initiated.

## SEC filing metadata
- accession: 0000950170-22-021564
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/0000950170-22-021564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/kura-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021564
- JSON: https://secwatch.observer/filing/0000950170-22-021564.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021564.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/0000950170-22-021564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.